Otsuka Novel Product GmbH (ONPG), Munich, Germany is Marketing Authorisation Holder of Deltyba® (delamanid) in Europe. ONPG is held at 100% share by Otsuka Pharmaceutical Co., Ltd. (OPC), Tokyo, Japan. OPC has expertise in TB drug screening, pre-clinical and clinical development. Delamanid has been successfully developed for the treatment of MDR-TB. A second novel anti-TB drug (OPC-167832) is currently in early stage clinical development.